<code id='77B795A692'></code><style id='77B795A692'></style>
    • <acronym id='77B795A692'></acronym>
      <center id='77B795A692'><center id='77B795A692'><tfoot id='77B795A692'></tfoot></center><abbr id='77B795A692'><dir id='77B795A692'><tfoot id='77B795A692'></tfoot><noframes id='77B795A692'>

    • <optgroup id='77B795A692'><strike id='77B795A692'><sup id='77B795A692'></sup></strike><code id='77B795A692'></code></optgroup>
        1. <b id='77B795A692'><label id='77B795A692'><select id='77B795A692'><dt id='77B795A692'><span id='77B795A692'></span></dt></select></label></b><u id='77B795A692'></u>
          <i id='77B795A692'><strike id='77B795A692'><tt id='77B795A692'><pre id='77B795A692'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:leisure time    - browse:8277
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time